{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T04:34:54Z","timestamp":1705811694478},"reference-count":32,"publisher":"Pharmaceutical Society of Japan","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2024,1,20]]},"DOI":"10.1248\/bpb.b23-00682","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T22:11:44Z","timestamp":1705702304000},"page":"232-239","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Inflammatory Bowel Disease with Biologics in Japan: A Single-Center, Retrospective Pharmacoeconomic Study"],"prefix":"10.1248","volume":"47","author":[{"given":"Atsuyuki","family":"Saisyo","sequence":"first","affiliation":[{"name":"Pharmacy Department, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haku","family":"Ishida","sequence":"additional","affiliation":[{"name":"Medical Informatics and Decision Sciences, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Kashibe","sequence":"additional","affiliation":[{"name":"Medical Informatics and Decision Sciences, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoyuki","family":"Oka","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Ube-Kohsan Central Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Hirano","sequence":"additional","affiliation":[{"name":"Medical Informatics and Decision Sciences, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miwako","family":"Takasago","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yutaka","family":"Uchida","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Okada","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taro","family":"Takami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kitahara","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Yamaguchi University Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Matsuoka K, Kobayashi T, Ueno F, <i>et al.<\/i> Evidence-based clinical practice guidelines for inflammatory bowel disease. <i>J. Gastroenterol.<\/i>, <b>53<\/b>, 305\u2013353 (2018).","DOI":"10.1007\/s00535-018-1439-1"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Nakase H, Uchino M, Shinzaki S, <i>et al.<\/i> Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. <i>J. Gastroenterol.<\/i>, <b>56<\/b>, 489\u2013526 (2021).","DOI":"10.1007\/s00535-021-01784-1"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Lichtenstein GR, Loftus EV Jr, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. Correction: ACG clinical guideline: management of Crohn\u2019s disease in adults. <i>Am. J. Gastroenterol.<\/i>, <b>113<\/b>, 1101 (2018).","DOI":"10.1038\/s41395-018-0120-x"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Lamb CA, Kennedy NA, Raine T, <i>et al.<\/i> British society of gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. <i>Gut<\/i>, <b>68<\/b> (Suppl. 3), s1\u2013s106 (2019).","DOI":"10.1136\/gutjnl-2019-318484"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Singh S, Murad MH, Fumery M, Dulai PS, Sandborn WJ. First- and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: an updated network meta-analysis. <i>Clin. Gastroenterol. Hepatol.<\/i>, <b>18<\/b>, 2179\u20132191.e6 (2020).","DOI":"10.1016\/j.cgh.2020.01.008"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Olivera P, Thiriet L, Luc A, Baumann C, Danese S, Peyrin-Biroulet L. Treatment persistence for infliximab <i>versus<\/i> adalimumab in Crohn\u2019s disease: a 14-year single-center experience. <i>Inflamm. Bowel Dis.<\/i>, <b>23<\/b>, 976\u2013985 (2017).","DOI":"10.1097\/MIB.0000000000001072"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Visuri I, Eriksson C, Ol\u00e9n O, Cao Y, M\u00e5rdberg E, Grip O, Gustavsson A, Hjortswang H, Karling P, Montgomery S, Myrelid P, Ludvigsson JF, Halfvarson J. Predictors of drug survival: a cohort study comparing anti-tumour necrosis factor agents using the Swedish inflammatory bowel disease quality register. <i>Aliment. Pharmacol. Ther.<\/i>, <b>54<\/b>, 931\u2013943 (2021).","DOI":"10.1111\/apt.16525"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) van den Reek JMPA, Kievit W, Gniadecki R, Goeman JJ, Zweegers J, van de Kerkhof PCM, Seyger MMB, de Jong EMGJ. Drug survival studies in dermatology: principles, purposes, and pitfalls. <i>J. Invest. Dermatol.<\/i>, <b>135<\/b>, 1\u20135 (2015).","DOI":"10.1038\/jid.2015.171"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. <i>Gut<\/i>, <b>53<\/b>, 1471\u20131478 (2004).","DOI":"10.1136\/gut.2004.041616"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Jiang J, Click B, Anderson AM, Koutroubakis IE, Rivers CR, Hashash JG, Dunn MA, Schwartz M, Swoger J, Barrie A, Regueiro M, Chang C, Binion DG. Group-based trajectory modeling of healthcare financial charges in inflammatory bowel disease: a comprehensive phenotype. <i>Clin. Transl. Gastroenterol.<\/i>, <b>7<\/b>, e181 (2016).","DOI":"10.1038\/ctg.2016.39"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Saisyo A, Yamaguchi M, Kashibe K, Ishida H, Hirano Y, Oka T, Tamura M, Takasago M, Uchida Y, Kouda K, Kitahara T. Pharmacoeconomic study of biologics for psoriasis treatment based on real-world drug survival. <i>Dermatol. Ther.<\/i>, <b>35<\/b>, e15375 (2022).","DOI":"10.1111\/dth.15375"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Ben-Horin S, Mao R, Chen M. Optimizing biologic treatment in IBD: objective measures, but when, how and how often? <i>BMC Gastroenterol.<\/i>, <b>15<\/b>, 178 (2015).","DOI":"10.1186\/s12876-015-0408-x"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Singh S, Heien HC, Sangaralingham LR, Schilz SR, Kappelman MD, Shah ND, Loftus EV Jr. Comparative effectiveness and safety of anti-tumor necrosis factor agents in biologic-naive patients with Crohn\u2019s disease. <i>Clin. Gastroenterol. Hepatol.<\/i>, <b>14<\/b>, 1120\u20131129.e6 (2016).","DOI":"10.1016\/j.cgh.2016.03.038"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Singh S, Heien HC, Sangaralingham LR, Schilz SR, Kappelman MD, Shah ND, Loftus EV. Comparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis. <i>Aliment. Pharmacol. Ther.<\/i>, <b>43<\/b>, 994\u20131003 (2016).","DOI":"10.1111\/apt.13580"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Lopetuso LR, Gerardi V, Papa V, Scaldaferri F, Rapaccini GL, Gasbarrini A, Papa A. Can we predict the efficacy of anti-TNF-\u03b1 agents? <i>Int. J. Mol. Sci.<\/i>, <b>18<\/b>, 1973 (2017).","DOI":"10.3390\/ijms18091973"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kawalec P. Indirect costs of inflammatory bowel diseases: Crohn\u2019s disease and ulcerative colitis. A systematic review. <i>Arch. Med. Sci.<\/i>, <b>12<\/b>, 295\u2013302 (2016).","DOI":"10.5114\/aoms.2016.59254"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Walter E, Hausberger SC, Gro\u00df E, Siebert U. Health-related quality of life, work productivity and costs related to patients with inflammatory bowel disease in Austria. <i>J. Med. Econ.<\/i>, <b>23<\/b>, 1061\u20131071 (2020).","DOI":"10.1080\/13696998.2020.1801187"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Manceur AM, Ding Z, Muser E, Obando C, Voelker J, Pilon D, Kinkead F, Lafeuille MH, Lefebvre P. Burden of Crohn\u2019s disease in the United States: long-term healthcare and work-loss related costs. <i>J. Med. Econ.<\/i>, <b>23<\/b>, 1092\u20131101 (2020).","DOI":"10.1080\/13696998.2020.1789649"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Rankala R, Mattila K, Voutilainen M, Mustonen A. Inflammatory bowel disease-related economic costs due to presenteeism and absenteeism. <i>Scand. J. Gastroenterol.<\/i>, <b>56<\/b>, 687\u2013692 (2021).","DOI":"10.1080\/00365521.2021.1908416"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Maeda Y, Tanaka R, Tatsuta R, Takano K, Hashimoto T, Ogata M, Hiramatsu K, Itoh H. Impact of inflammation on intra-individual variation in trough voriconazole concentration in patients with hematological malignancies. <i>Biol. Pharm. Bull.<\/i>, <b>45<\/b>, 1084\u20131090 (2022).","DOI":"10.1248\/bpb.b22-00097"},{"key":"21","unstructured":"21) Fukuda T, Shiroiwa T, Ikeda SY. Guideline for economic evaluation of healthcare technologies in Japan. <i>J. Natl. Inst. Public Health<\/i>, <b>62<\/b>, 625\u2013640 (2013)."},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Borzan V, Fric VO, Borzan B. Pharmacoeconomic analysis of different biologic therapies in inflammatory bowel disease patients in 1 tertiary center in Croatia: 2729. <i>Am. J. Gastroenterol.<\/i>, <b>112<\/b>, S1481 (2017).","DOI":"10.14309\/00000434-201710001-02730"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Eder K, Baffy N, Falus A, Fulop AK. The major inflammatory mediator interleukin-6 and obesity. <i>Inflamm. Res.<\/i>, <b>58<\/b>, 727\u2013736 (2009).","DOI":"10.1007\/s00011-009-0060-4"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Maaser C, Sturm A, Vavricka SR, <i>et al.<\/i> ECCO-ESGAR guideline for diagnostic assessment in IBD part 1: initial diagnosis, monitoring of known IBD, detection of complications. <i>J. Crohn\u2019s Colitis<\/i>, <b>13<\/b>, 144\u2013164K (2019).","DOI":"10.1093\/ecco-jcc\/jjy113"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) D\u0105bek-Drobny A, Kaczmarczyk O, Pi\u0105tek-Guziewicz A, Wo\u017aniakiewicz M, Pa\u015bko P, Dobrowolska-Iwanek J, Wo\u017aniakiewicz A, Targosz A, Ptak-Belowska A, Zagrodzki P, Zwoli\u0144ska-Wcis\u0142o M. Application of the clustering technique to multiple nutritional factors related to inflammation and disease progression in patients with inflammatory bowel disease. <i>Nutrients<\/i>, <b>14<\/b>, 3960 (2022).","DOI":"10.3390\/nu14193960"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Buczy\u0144ska A, Grzybowska-Chlebowczyk U. Prognostic factors of biologic therapy in pediatric IBD. <i>Children <\/i>(Basel), <b>9<\/b>, 1558 (2022).","DOI":"10.3390\/children9101558"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Schoenefuss F, Hoffmann P. Serum \u03b3-globulin and albumin concentrations predict secondary loss of response to anti-TNF\u03b1 in inflammatory bowel disease patients. <i>Eur. J. Gastroenterol. Hepatol.<\/i>, <b>31<\/b>, 1563\u20131568 (2019).","DOI":"10.1097\/MEG.0000000000001493"},{"key":"28","unstructured":"28) Hiwatashi N. Enteral hyperalimentation in the management of inflammatory bowel disease. <i>Rinsho Geka<\/i>, <b>40<\/b>, 73\u201380 (1985)."},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Hirai F, Ishida T, Takeshima F, Yamamoto S, Yoshikawa I, Ashizuka S, Inatsu H, Mitsuyama K, Sou S, Iwakiri R, Nozaki R, Ohi H, Esaki M, Iida M, Matsui T. Effect of a concomitant elemental diet with maintenance anti-tumor necrosis factor-\u03b1 antibody therapy in patients with Crohn\u2019s disease: a multicenter, prospective cohort study. <i>J. Gastroenterol. Hepatol.<\/i>, <b>34<\/b>, 132\u2013139 (2019).","DOI":"10.1111\/jgh.14361"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) de Sire R, Nardone OM, Testa A, Calabrese G, Caiazzo A, Castiglione F. Exclusive enteral nutrition in adult Crohn\u2019s disease: an overview of clinical practice and perceived barriers. <i>Clin. Exp. Gastroenterol.<\/i>, <b>14<\/b>, 493\u2013501 (2021).","DOI":"10.2147\/CEG.S267172"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Barbier L, Ebbers HC, Declerck P, Simoens S, Vulto AG, Huys I. The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. <i>Clin. Pharmacol. Ther.<\/i>, <b>108<\/b>, 734\u2013755 (2020).","DOI":"10.1002\/cpt.1836"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Funaki A, Hirata I, Matsui H, Isezaki T, Funakoshi R. Factors affecting patients\u2019 acceptance of switching to biosimilars are disease-dependent: a cross-sectional study. <i>Biol. Pharm. Bull.<\/i>, <b>46<\/b>, 128\u2013132 (2023).","DOI":"10.1248\/bpb.b22-00429"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/1\/47_b23-00682\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,20]],"date-time":"2024-01-20T03:18:10Z","timestamp":1705720690000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/47\/1\/47_b23-00682\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,20]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b23-00682","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,20]]},"article-number":"b23-00682"}}